Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis

Journal of Rheumatology

Volumn 33, Issue 6, 2006, Pages 1108-1112

  Vera Lastra, Olga ^a   Jara, Luis J ^a,c   Medina, Gabriela ^b   Rojas, Juan L ^b   Velásquez, Francisco ^b   Ariza, Raul ^a   Normandía, Asunción ^b   Fuentes, Margarita ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b IMMS   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Hyperprolactinemia; Microadenoma; Prolactin; Systemic sclerosis

Indexed keywords

METOCLOPRAMIDE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOTHALAMUS; LABORATORY TEST; METOCLOPRAMIDE TEST; MICROADENOMA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SELLA TURCICA; SYSTEMIC SCLEROSIS;

ADENOMA; ADULT; FEMALE; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SELLA TURCICA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33744733743     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Seibold JR. Scleroderma. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 5th ed. Philadelphia: W.B. Saunders; 1997:1133-62.
2. Steen VD, Medsger TA. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990;16:1-10.
3. Lekakis J, Maurikaki M, Papamichael C, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998;136:905-12.
4. La Montagna G, Baruffo A, Bouno G, Valentini G. Dehydroepiandrosterone sulphate serum levels in systemic sclerosis. Clin Exp Rheumatol 2001;19:21-6.
5. Molnar I, Czirjak C. Euthyroid sick syndrome and inhibitors effect of sera on the activity of thyroid 5′-deiodinase in systemic sclerosis. Clin Exp Rheumatol 2000;18:719-24.
6. Straub RH, Zeuner M, Lock G, Schoelmerich J. High prolactin and low dehydro-epiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 1997;36:426-32.
7. Shahin AA, Abdoh S, Abdelrazik M. Prolactin and thyroid hormones in patients with systemic sclerosis: correlation with disease manifestations and activity. Z Rheumatol 2002;61:703-9.
8. Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M. Selective stimulation of collagen synthesis in the presence of co-stimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003;48:798-806.
9. El-Salhy M, Suhr O, Danielsson A. Peptide YY in gastrointestinal disorders. Peptides 2002;23:397-402.
10. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmunity Rev 2002;1:360-4.
11. Vance ML, Thornes MO. Prolactinomas. Endocrinol Metab Clin N Am 1987;16:731-53.
12. Tansey MJ, Schlechte JA. Pituitary production of prolactin and prolactin-suppressing drugs. Lupus 2001;10:660-4.
13. Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann Intern Med 1990;112:925-31.
14. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304:156-8.
15. Chidiac RM, Aron DC. Incidentalomas. A disease of modern technology. Endocrinol Metab Clin North Am 1997;26:233-53.
16. Chambers EF, Turski PA, LaMasters D, Newton TH. Regions of low density in the contrast-enhanced pituitary gland: Normal and pathological processes. Radiology 1982;144:109-13.
17. Frohman LA. Disease of anterior pituitary. In: Felling P, Baxter JD, Frohman LA, editors. Endocrinology and metabolism, 3th ed. New York: McGraw-Hill; 1995:289-383.
18. Hilty C, Bruhlmann P, Sprott H, et al. Altered diurnal rhythm of prolactin in systemic sclerosis. J Rheumatol 2000;27:2160-5.
19. Kucharz EJ, Jarczyk R, Jonderko G, Rubisz-Brezezinska J, Brzezinska-Wcislo L. High level of prolactin in patients with systemic sclerosis [letter]. Clin Rheumatol 1996;15:314.
20. Walker SE, Jacobson JD. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 2000;26:713-36.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
22. Vance LM, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ, editor. Endocrinology. Philadelphia: W.B. Saunders;1989:408-18.
23. Zoli A, Ferlisi EM, Pompa A, et al. Basal and after-stimuli test for prolactinemia in systemic lupus erythematosus. Ann NY Acad Sci 1999;876:155-8.
24. La Montagna G, Meli R, Criscuolo T, D'Angelo S, Valentini G. Bioactivity of prolactin in systemic sclerosis. Clin Exp Rheumatol 2004;22:145-50.
25. Mendez I, Alcocer-Varela J, Parra A, et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus 2004;13:45-53.
26. El-Azouzi M, Hsu DW, Black PM, et al. The importance of dopamine in the pathogenesis of experimental prolactinomas. J Neurosurg 1990;72:273-81.
27. McMurray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994;21:843-50.
28. Reuman PD. First reported pediatric case of systemic lupus erythematosus associated with prolactinoma. Arthritis Rheum 2004;50:3616-8.
29. Funauchi M, Ikoma S, Enomoto H, et al. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 1998;16:479-82.
30. Annegers JF, Coulam CB, Abboud CP, Laws ER Jr, Kurland LT. Pituitary adenoma in Olmstead County, Minnesota, 1935-1977: A report of an increasing incidence of diagnosis in woman of childbearing age. Mayo Clin Proc 1978;53:641-3.
31. Miyai K, Ichihara K, Kondo K, Mori S. Asymptomatic hyperprolactinaemia and prolactinaemia in the general population - mass screening by paired assays of serum prolactin. Clin Endocrinol 1986;25:549-54.
32. Robinson DB, Michaels RD. Empty sella resulting from the spontaneous resolution of a pituitary macroadenoma. Arch Intern Med 1992;152:1920-3.
33. Gsponer J, De Tribolet N, Deruaz JP, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine Baltimore 1999;78:236-69.
34. Kahl LE, Medsger TA, Klein I. Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol 1985;12:990-1.
35. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7.
36. Schelechte JA. The macroprolactin problem. J Clin Endocrinol Metab 2002;87:5408-9.
37. La Montagna G, Baruffo A, Pascuali D, Bellastella A, Tirri G, Sinisi AA. Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis. Rheumatology Oxford 2001;40:310-14.
38. Giusti B, Serrati S, Margheri F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005;52:3618-28.
39. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-38.
40. Clapp C, Weiner R. A specific, high affinity, saturable binding site for the 16-KD fragment of prolactin on capillary endothelial cells. Endocrinology 1992;130:1380-6.
41. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;120:817-20.